🇺🇸 FDA
Patent

US 11731968

Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

granted A61KA61K31/4745A61P

Quick answer

US patent 11731968 (Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death) held by HEPAREGENIX GMBH expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HEPAREGENIX GMBH
Grant date
Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/4745, A61P, A61P31/20